retatrutide phase 2 trial weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Triple hormone receptor agonist retatrutide

Microdosing is also harder with oral GLP-1s

In conclusion, the effects of GLP-1Ra (i.e., semaglutide and liraglutide), including weight loss, slight BMD loss, and increased CTX, resembled to those observed with calorie restriction interventions [7, 9]

However, it should be noted that GLP-1RAs can enhance sympathetic activity, potentially increasing heart rate and blood pressure, despite their cardioprotective properties [66]

Result Characteristics of included meta-analyses A total of 5617 articles were retrieved from five databases

Injections are more likely to cause injection-site reactions such as redness, itching, or mild swelling

The surgical technique is based on your anatomy, not the medication itself